EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

Serum Neurofilament Light Is Associated With Future Disease Activity in Clinically Isolated Syndrome and Early Multiple Sclerosis Only After Non‐Optic Neuritis Onset

Philipp Klyscz iD, Klemens Ruprecht, Lina Carlotta Anderhalten, Tanja Schmitz-Hübsch iD, Jens Kuhle, Tatiana Usnich, Judith Bellmann-Strobl, Friedemann Paul, Patrick Schindler, Susanna Asseyer iD

European Journal of Neurology · 2025

DOI: 10.1111/ene.70375 ↗

At a glance

Journal article in European Journal of Neurology, 2025. Written by Philipp Klyscz and 9 co-authors. Institution: Experimental and Clinical Research Center, a Cooperation Between Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité,…. Major MEDLINE topics: Neurofilament Proteins, Multiple Sclerosis, Demyelinating Diseases. 36 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Novartis.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

We compared the prognostic value of serum neurofilament light chain (sNFL) and glial fibrillary acidic protein (sGFAP) for clinical and radiologic disease activity among patients with clinically isolated syndrome or early multiple sclerosis (MS) with optic neuritis (pwON) and non‐optic neuritis (pwNON) as the first manifestation.

Methods

Patients within 7 months (pwON and pwNON) from disease onset and patients with MS with a disease duration longer than 12 months (pwMS) as controls were included. sNFL and sGFAP were analyzed at baseline and at follow‐ups using SIMOA technology. Linear mixed models and Cox regression analyses were applied.

Results

We included 165 samples of 86 patients (18 pwON, 46 pwNON, 21 pwMS). Median follow‐up time was 80 months. Mean sNFL z scores were higher in pwNON (1.06) than pwON (0.53) and pwMS (0.94). In pwNON, but not pwON, higher sNFL z scores were associated with an elevated risk for a subsequent attack (pwNON: HR 1.63 [95% CI 1.12 to 2.27], p = 0.005; pwON: HR 0.80 [95% CI 0.51–2.27], p = 0.318) and new MRI T2 lesions (pwNON: HR 1.66 [95% CI 1.31 to 2.11], p < 0.001; pwON: HR 1.16 [95% CI 0.82 to 1.63], p = 0.404). sGFAP z scores were associated with a lower risk of a subsequent attack in pwON (HR 0.34 [95% CI 0.12 to 0.98], p = 0.047). Conclusion sNFL but not sGFAP predicted future clinical and MRI disease activity only in pwNON, potentially suggesting that the prognostic value of sNFL may depend on the type of the first manifestation.

Subjects

MeSH terms (MEDLINE)

Neurofilament ProteinsMultiple SclerosisDemyelinating DiseasesHumansFemaleMaleAdultOptic NeuritisMiddle AgedGlial Fibrillary Acidic ProteinDisease ProgressionPrognosisBiomarkersFollow-Up StudiesMagnetic Resonance Imaging

Author keywords

biomarkerglial fibrillary acidic proteinmultiple sclerosisneurofilamentoptic neuritis

Substances

Neurofilament Proteinsneurofilament protein LGlial Fibrillary Acidic ProteinBiomarkers

Authors and institutions

  • Experimental and Clinical Research Center, a Cooperation Between Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité, Universitätsmedizin Berlin, Berlin, Germany.
  • Department of Neurology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Division of Neuroimmunology, Department of Neurology, University of Heidelberg, Heidelberg, Germany.
  • Neuroscience Clinical Research Center (NCRC), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Neurology, Departments of Clinical Research and Biomedicine, University Hospital Basel, University of Basel, Basel, Switzerland.

ORCID profiles: Philipp Klyscz, Tanja Schmitz-Hübsch, Susanna Asseyer

Funding

  • Novartis

Cite

APA

Klyscz, P., Ruprecht, K., Anderhalten, L. C., Schmitz-Hübsch, T., Kuhle, J., Usnich, T., Bellmann-Strobl, J., Paul, F., Schindler, P., & Asseyer, S. (2025). Serum Neurofilament Light Is Associated With Future Disease Activity in Clinically Isolated Syndrome and Early Multiple Sclerosis Only After Non‐Optic Neuritis Onset. European Journal of Neurology. https://doi.org/10.1111/ene.70375

Vancouver

Klyscz P, Ruprecht K, Anderhalten LC, Schmitz-Hübsch T, Kuhle J, Usnich T, et al. Serum Neurofilament Light Is Associated With Future Disease Activity in Clinically Isolated Syndrome and Early Multiple Sclerosis Only After Non‐Optic Neuritis Onset. European Journal of Neurology. 2025. doi:10.1111/ene.70375

BibTeX
@article{Klyscz2025,
  author = {Klyscz, Philipp and Ruprecht, Klemens and Anderhalten, Lina Carlotta and Schmitz-Hübsch, Tanja and Kuhle, Jens and Usnich, Tatiana and Bellmann-Strobl, Judith and Paul, Friedemann and Schindler, Patrick and Asseyer, Susanna},
  title = {Serum Neurofilament Light Is Associated With Future Disease Activity in Clinically Isolated Syndrome and Early Multiple Sclerosis Only After Non‐Optic Neuritis Onset},
  journal = {European Journal of Neurology},
  year = {2025},
  doi = {10.1111/ene.70375}
}
Start for free →